This study is a multicenter, open-label, active-controlled, randomized, non-inferiority trial to assess the efficacy and safety of rivaroxaban for thromboprophylaxis in children with giant coronary aneurysms after Kawasaki disease. Participants will be randomly assigned to the control or experiment groups. Randomization ratio will be 1:1. The control group will receive warfarin plus aspirin or clopidogrel, and the experiment group will receive Rivaroxaban plus aspirin or clopidogrel. This study will last for 6 months. Baseline characters, efficacy outcomes, bleeding events, adverse events and compliance of intervention of each participant will be collected. Two-dimensional echocardiography will be performed at admission and each scheduled visits to detect whether new thrombogenesis occurred in the giant coronary aneurysms.
To evaluate the efficacy and safety of rivaroxaban compared to warfarin for thromboprophylaxis in children with giant coronary aneurysms after Kawasaki disease